ISRCTN31894936已完成不适用
An open-label follow-on study to assess the ongoing safety of MBP8298 in subjects with secondary progressive multiple sclerosis
BioMS Medical (Canada)0 个研究点目标入组 600 人开始时间: 2007年5月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Completion of treatment and all required evaluations of MBP8298-SP-01(ISRCTN record of this trial at http://www.controlled-trials.com/ISRCTN98373474)
- •2. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements
- •3. Subjects must be reliable, compliant, and agree to cooperate with all trial evaluations in the investigator?s opinion
排除标准
- •1. Pregnancy or desire to become pregnant
- •2. Use of any concomitant disease modifying therapy for Multiple Sclerosis (MS)
研究者
相似试验
已完成
2 期
An Open label Follow-On Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis.MS10012303Multiple SclerosisNL-OMON32699ICON Clinical Research35
进行中（未招募）
不适用
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyprimary hyperoxaluriaMedDRA version: 9.1Level: LLTClassification code 10020703Term: HyperoxaluriaEUCTR2007-006187-30-DEOxThera, Inc.42
进行中（未招募）
1 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyprimary hyperoxaluriaMedDRA version: 9.1 Level: LLT Classification code 10020703 Term: HyperoxaluriaEUCTR2007-006187-30-GBOxThera, Inc.
尚未招募
3 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy StudyPrimary Hyperoxaluria (PH)1002160510038430NL-OMON31883OxThera Inc.4
进行中（未招募）
1 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyEUCTR2007-006187-30-FROxThera, Inc.